Clinical Research Directory
Browse clinical research sites, groups, and studies.
Acalabrutinib in Patients With Chronic Lymphocytic Leukemia With Direct Oral Anticoagulation (CICERO)
Sponsor: iOMEDICO AG
Summary
The goal of CICERO is to investigate the clinical outcome with a particular focus on prospective data on safety using acalabrutinib (+/- obinutuzumab) in CLL patients receiving co-medication with DOACs (edoxaban, rivaroxaban, dabigatran, apixaban) irrespective of treatment line.
Official title: A Non-interventional, Prospective, Open-label, Observational Study Evaluating the Effectiveness and Safety of Acalabrutinib (Calquence®) in Patients With Chronic Lymphocytic Leukemia (CLL) Receiving Direct Oral Anticoagulation (DOAC).
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
45
Start Date
2022-10-12
Completion Date
2026-03-31
Last Updated
2025-04-30
Healthy Volunteers
No
Conditions
Interventions
Calquence
acalabrutinib (+/- obinutuzumab) according to Calquence® SmPC.
Calquence
acalabrutinib according to Calquence® SmPC.
Locations (1)
Prof. Dr. Fenchel & Dr. Winkler MVZ Träger GbR
Saalfeld, Thuringia, Germany